Hepatitis

Feature Article

ID Specialist Involvement Key to Successfully Treating Hepatitis C

ID Specialist Involvement Key to Successfully Treating Hepatitis C

ID specialists need to take a major role in the implementation of new treatments for HCV.

The relative risk for healthcare-associated infections has decreased in the last 15 years due to improvements in awareness of risk associated with devices, infection control, and evidence-based practice regarding use of devices.

Latest News

Liver and Treatment Failure Cases Linked With Newer HCV Antivirals

Liver and Treatment Failure Cases Linked With Newer HCV Antivirals

While direct-acting antivirals represent an important advance in the treatment of hepatitis C virus infection, further investigation is needed to understand the reasons for the cases of liver failure and antiviral failure reported to the FDA.

HCV Infection Linked to Nonhepatic Cancers in the Elderly

HCV Infection Linked to Nonhepatic Cancers in the Elderly

In the elderly population, hepatitis C virus infection is associated with cancers other than hepatocellular carcinoma, such as bile duct and pancreatic cancers and diffuse large B-cell lymphoma.

Neuropsychiatric Impairment in Patients With HCV Despite Virus Clearance

Neuropsychiatric Impairment in Patients With HCV Despite Virus Clearance

Neuropsychiatric syndrome not linked to virus in hepatitis C infection.

Targeted CBT for HCV Patients Helps to Reduce Pain and Substance Use

Targeted CBT for HCV Patients Helps to Reduce Pain and Substance Use

Customized CBT reduced substance use disorder, pain severity, and pain interference in veterans with HCV.

Short-Course Tocilizumab May Increase HBV Reactivation in RA

Short-Course Tocilizumab May Increase HBV Reactivation in RA

Three-dose tocilizumab combined with csDMARDs might increase the risk of HBV reactivation in RA patients with chronic HBV infection.

FDA Grants Priority Review to Fixed-Dose Pan-Genotypic HCV Regimen

FDA Grants Priority Review to Fixed-Dose Pan-Genotypic HCV Regimen

Priority Review granted to the NDA of glecaprevir/pibrentasvir (G/P; AbbVie) for the treatment of genotypes 1-6 chronic hepatitis C virus infection.

Telemedicine Improves Hepatitis C Treatment Rates in Rural Areas

Telemedicine Improves Hepatitis C Treatment Rates in Rural Areas

Using telemedicine consults with specialists to support PCPs enhanced the treatment rates in hepatitis C in rural areas.

Reducing Diabetes Risk Key to Eradicating HCV in Coinfected Patients

Reducing Diabetes Risk Key to Eradicating HCV in Coinfected Patients

Sustained viral response correlated with a significant decrease in the risk of diabetes mellitus and a trend towards decrease in chronic renal failure, according to a study.

Prophylactic Lamivudine Reduces HBV Flares During Chemotherapy

Prophylactic Lamivudine Reduces HBV Flares During Chemotherapy

Patients with breast cancer who have chronic HBV infection have fewer flares while undergoing chemotherapy if they are treated with prophylactic lamivudine.

Short-Duration Triple DAA for Chronic HCV With Portal Hypertension

Short-Duration Triple DAA for Chronic HCV With Portal Hypertension

Trial finds the combination of simeprevir, daclatasvir, and sofosbuvir generally safe and well tolerated in HCV patients with decompensated liver disease.

Sign Up for Free e-newsletters